aTyr Pharma
ATYR
41 hedge funds and large institutions have $172M invested in aTyr Pharma in 2021 Q3 according to their latest regulatory filings, with 16 funds opening new positions, 17 increasing their positions, 5 reducing their positions, and 3 closing their positions.
4,578% more capital inflows, than outflows
Capital inflows: $73.6M | Capital outflows: $1.57M
433% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 3
240% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 5
163% more call options, than puts
Call options by funds: $8.09M | Put options by funds: $3.08M
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
46% more funds holding
Funds holding: 28 → 41 (+13)
29.02% more ownership
Funds ownership: 43.05% → 72.07% (+29%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$21.6M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$14.3M |
| 3 |
VR Adviser
New York
|
+$9.36M |
| 4 |
Tang Capital Management
San Diego,
California
|
+$6.66M |
| 5 |
BBA
Baker Bros. Advisors
New York
|
+$3.74M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alyeska Investment Group
Chicago,
Illinois
|
-$1.11M |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
-$208K |
| 3 |
TI
Telemetry Investments
New York
|
-$83.7K |
| 4 |
XTX Topco
George Town,
Cayman Islands
|
-$60K |
| 5 |
BlackRock
New York
|
-$47.1K |
ATYR Hedge Fund Activity: Q3 2021 in Review
41 of the 5,731 institutional investors tracked by Wall St. Rank reported a position in aTyr Pharma (ATYR) for Q3 2021, worth a combined $172M — up 410% from $33.8M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new ATYR positions and 3 closed out — a net gain of 13 holders — while 17 added to existing stakes and 5 trimmed.
The largest buyer was Federated Hermes, adding an estimated $21.6M. The largest seller was Alyeska Investment Group, cutting an estimated $1.11M.
- 41 institutional investors held aTyr Pharma (ATYR) as of Q3 2021, up from 28 in Q2 2021.
- Funds reported $172M of aTyr Pharma stock for Q3 2021, up 410% quarter-over-quarter.
- 16 funds opened new aTyr Pharma positions in Q3 2021 and 3 closed out, a net change of +13 holders.
- The largest aTyr Pharma buyer in Q3 2021 was Federated Hermes, an estimated $21.6M added.
- The largest aTyr Pharma seller in Q3 2021 was Alyeska Investment Group, an estimated $1.11M sold.
Based on aggregated 13F filings for Q3 2021.